Acer has to conduct new trial of rare disease drug, FDA says
Shares of the company fell dramatically Tuesday after it announced that the agency had rejected its application for the drug celiprolol in vascular Ehlers-Danlos syndrome.
Edsivo
Shares of the company fell dramatically Tuesday after it announced that the agency had rejected its application for the drug celiprolol in vascular Ehlers-Danlos syndrome.